Results from pre-clinical research show iron-like compound hold promise for treating patients with glioblastoma, an aggressive brain cancer
DST-backed researchers from Pune demonstrate targeted gene-silencing approach that significantly inhibits tumor growth with minimal toxicity
The conference highlighted research suggesting that deuterium levels may influence key biological processes
The newly licensed platform enables precise control over both the drug-to-antibody ratio and payload attachment sites in single- and dual-payload ADCs
The investigational therapy, MDX2003, is designed to go after cancer cells with a multi-pronged immune attack
While many cases are treatable, a subset can become highly aggressive, spreading to distant organs and resisting conventional therapies
The partnership aims to fuse antibody-drug conjugation (ADC) technology with targeted protein degradation
Ac-225, an alpha-emitting radionuclide, can be paired with molecules designed to selectively target cancer cells.
Phase I EPRAD study of DT-9081 demonstrated a favorable safety profile
A next-generation, cell-based immunotherapy, CAR-T therapy engineers a patient’s own immune cells to detect and destroy cancer
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
